Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionXTX Topco Ltd
Latest Disclosed Ownership14,317 shares
Latest Disclosed Value $ 43,953
XTX Topco Ltd reports 70.12% decrease in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On May 15, 2026 - XTX Topco Ltd filed a 13F-HR form disclosing ownership of 14,317 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $43,953 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 47,908 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of -70.12% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 14,317 -33,591 -70.12 44 -77.95 0.0008
2026-02-17 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 47,908 24,421 103.98 196 71.05 0.0051
2025-11-14 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 23,487 -607,719 -96.28 115 -96.43 0.0059
2025-08-12 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 631,206 631,206 3,194 0.1324
2025-05-08 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 0 -83,547 -100.00 0 -100.00
2025-02-13 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 83,547 83,547 565 0.0464
2024-05-13 2024-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 0 -15,349 -100.00 0 -100.00
2024-02-13 2023-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 15,349 15,349 151 0.0331
2023-08-14 2023-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 0 -48,138 -100.00 0 -100.00
2023-05-12 2023-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 48,138 30,124 167.23 321 132.61 0.0673
2023-02-14 2022-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 18,014 7,714 74.89 139 25.45 0.0295
2022-11-14 2022-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 10,300 10,300 110 0.0272
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.